Estun Automation Gets Breakthrough Therapy Status for Reproductive Cancer Drug
CSPC Innovation Pharmaceutical (SHE:300765) unit Jushi Biopharm obtained China's breakthrough therapy designation for its injectable SYS6043. The drug is indicated for platinum-resistant ovarian cancer, primary peritoneal cancer and fallopian tube cancer, according to a Thursday filing with the Shenzhen bourse. Shares of the pharmaceutical company closed 6% higher Friday.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.